Potential drugs targeting microglia: current knowledge and future prospects

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Central nervous system (CNS) inflammation involves microglia, the resident immune cells.
• Microglia activation is crucial in injury response but chronic activation causes neurotoxicity, exacerbating neurodegenerative diseases like Parkinson's and Alzheimer's.
• Controlling microglial activation is a key research focus for treating CNS pathologies.

Purpose of the Study:

• To review current drugs that reduce microglial activation.
• To explore their molecular targets and signaling pathways.
• To discuss emerging therapies like epidrugs and targeted drug delivery for neuroprotection.

Main Methods:

• Comprehensive literature review of existing drugs and novel therapeutic approaches.
• Analysis of molecular targets and subcellular signaling networks involved in microglial activation.
• Evaluation of targeted drug delivery systems for CNS applications.

Main Results:

• Several compounds can attenuate microglial activation, but often lack specificity and cause side effects.
• Understanding molecular targets and signaling pathways is crucial for developing effective treatments.
• Emerging strategies like epidrugs and targeted delivery show promise for mitigating neurotoxicity.

Conclusions:

• Targeting microglial activation is essential for managing neuroinflammation and neurodegeneration.
• Further research into specific molecular pathways and advanced drug delivery is needed.
• Developing targeted therapies can improve treatment efficacy and reduce side effects in CNS disorders.